Fibrous Dysplasia Of Bone
Conditions
Keywords
McCune-Albright Syndrome, Rickets, Osteomalacia, Metabolic Bone Disorders
Brief summary
Background: Fibrous dysplasia (FD) is a disorder that affects bone growth. Affected bone tissue is weakened, and people with FD are prone to deformities, fractures, and other problems. People with FD may also have low blood phosphate levels. This can make bones even weaker. Better treatments are needed. Objective: To test a study drug (burosumab) in people with FD who have low blood phosphate levels. Eligibility: People aged 1 year or older who have FD and low blood phosphate levels. Design: Participants will visit the NIH 3 times in 48 weeks. Each visit will last 5 to 7 days. Participants will self-inject burosumab under the skin in their belly, upper arm, or thigh. They (or a caregiver) will do this at home 1 or 2 times a month. They will be trained in person on how to inject the drug. Home injections will be guided via telehealth. During NIH visits, participants will have a physical exam with blood and urine tests. They will have x-rays of different parts of their body. They will have a radioactive tracer injected into their vein; then they will have a bone scan. They will have tests to assess their strength, walking, and movement. They will complete questionnaires about their pain, mobility, and fatigue levels. Adult participants may have bone biopsies. These will be done under anesthesia with sedation. Small samples of FD-affected bone will be removed for study. Between NIH visits, participants will go to a local laboratory for blood and urine tests. Child participants will have an additional follow-up visit 2 weeks after the final NIH visit.
Detailed description
Study Description: This will be a phase 2, open-label, single-arm study to evaluate the safety and efficacy of burosumab to normalize serum phosphate levels in subjects with fibrous dysplasia (FD) and fibroblast growth factor 23 (FGF23)-mediated hypophosphatemia. Objectives: Primary Objective: -Evaluate the efficacy of burosumab to normalize serum phosphate levels in subjects with FD and FGF23-mediated hypophosphatemia at 48 weeks. Secondary Objectives: * Evaluate the efficacy of burosumab to normalize serum phosphate levels in subjects with FD and FGF23-mediated hypophosphatemia at 24 weeks. * Evaluate the safety and tolerability of burosumab in patients with FD. * Evaluate the effect of burosumab on increasing serum phosphate and additional mineral markers. * Evaluate the impact of burosumab on FD lesion activity. * Evaluate the effect of burosumab on functional parameters. * Evaluate the effect of burosumab on pain and health-related quality of life. Endpoints: Primary Endpoint: -The proportion of subjects achieving serum phosphate levels within the target range (Z-score -1 to +2) at Week 48. Secondary Endpoints: * Proportion of subjects achieving serum phosphate levels within the target range (Z-score -1 to +2) at Week 24. * Adverse events and clinical safety laboratory tests for up to 4 weeks after the final burosumab dose (48 weeks for adult subjects, 50 weeks for pediatric subjects). * Change and percent change from baseline to post-baseline visits in serum phosphate, serum 1,25(OH)2D, ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR). * Change in FD lesion activity using Fluorine-18 Sodium Fluoride Positron Emission Tomography/Computed Tomography (18F-NaF PET/CT) total lesion activity from baseline to 48 weeks * Change and percent change in serum bone turnover markers, including procollagen 1 N-terminal propeptide (P1NP), beta crosslaps C-telopeptides (CTX), osteocalcin, and bone-specific alkaline phosphatase from baseline to 48 weeks. * Change in FD lesion histology and cell proliferation as assessed by minimally invasive bone biopsies from baseline to 48 weeks (adults with capacity to consent only) from baseline to 48 weeks * Skeletal changes assessed on skeletal survey at baseline and 48 weeks * Change from baseline to 48 weeks in: * Muscle strength * Range-of-motion * Walking speed (9-minute walk) Change from baseline to 48 weeks in patient reported outcomes measures: * Short Form Health Survey 36 (SF-36): adults * Short Form Health Survey 10 (SF-10): children * Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity: Pediatric and Parent Proxy version 1.0, Adult version 2.0 * PROMIS Pain Interference: Pediatric and Parent Proxy v 2.0, Adult v 1.1 * PROMIS Mobility: Pediatric and Parent Proxy version 2.0, Adult Mobility Lower Extremity v 1.0 * PROMIS Fatigue: Pediatric and Parent Proxy v 2.0, Adult FACIT 13a v1.0 * Activities of Daily Living Questions: adults and children
Interventions
DRUGBurosumab
Human recombinant monoclonal antibody to fibroblast growth factor-23 (FGF23)
Sponsors
National Institute of Dental and Craniofacial Research (NIDCR)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Confirmed diagnosis of fibrous dysplasia * Serum phosphate \<10th percentile for age and sex, AND intact serum FGF23 \>=30 pg/mL * Age \>=1 year * Provision of signed and dated informed consent/assent form * Stated willingness of subject or Legally Authorized Representative (LAR) to comply with all study procedures and availability for the duration of the study * For females of reproductive potential: agreement to use highly effective contraception for during study participation. Highly effective contraception methods include: * Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. * Male sterilization (at least 6 months prior to screening). For female participants on the study the vasectomized male partner should be the sole partner for that participant. * Combination of the following (a+b or a+c, or b+c): * Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception * Placement of an intrauterine device (IUD) or intrauterine system (IUS) * Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository * For males of reproductive potential: use of condoms or other methods described above to ensure effective contraception with partner * Minimum body weight of 7.5 kilograms
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: * Pregnancy or lactation * Known allergic reactions to burosumab or drug component * Treatment with another investigational drug within 30 days of screening * Treatment with burosumab within 30 days of screening * Have any condition which in the opinion of the PI could present a concern for subject safety or difficulty with data interpretation * Severe renal impairment or end stage renal disease, defined as: pediatric patients with estimated glomerular filtration rate (eGFR) 15 mL/min/1.73m2 to 29 mL/min/1.73m2 or end stage renal disease (eGFR \< 15 mL/min/1.73m2), adult patients with creatinine clearance (CLcr) 15 mL/min to 29 mL/min or end stage renal disease (CLcr \< 15 mL/min)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Participants With Serum Phosphate Levels Within the Target Range at Week 48 | Week 48 | The proportion of participants who achieved serum phosphate levels within the target range (Z-score -1 to +2) at week 48. Analysis was done by dividing the number of number of participants who achieved serum level by the number of participants analyzed. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participants With Adverse Event by Grade | 48 weeks for adult participants; 50 weeks for pediatric participants | Number participants with any adverse events by grade, up to 4 weeks after the final burosumab dose, was assessed using the National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental ADL. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. |
| Participants With Related Adverse Event | 48 weeks for adult participants; 50 weeks for pediatric participants | Participants with related adverse events up to 4 weeks after the final burosumab dose (48 weeks for adult subjects, 50 weeks for pediatric subjects). Adverse event was assessed using the National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Related adverse event means that there are available evidence that suggests that there is a reasonable possibility that the study drug caused the adverse event. |
| Proportion of Participants With Serum Phosphate Levels Within the Target Range at Week 24 | Week 24 | The proportion of participants who achieved serum phosphate levels within the target range (Z-score -1 to +2) at week 24. Analysis was done by dividing the number of number of participants who achieved serum level by the number of participants analyzed. |
| Proportion of Participants With Serum Phosphate Levels Above the Target Range (Z-score >+2) | Between baseline and week 48 | The proportion of participants who achieved serum phosphate levels above the target range (Z-score \>+2) at any timepoint between baseline and week 48. Analysis was done by dividing the number of number of participants who achieved serum level above the target range by the number of participants analyzed. |
| Change in Serum Phosphate Level | Week 48 minus baseline | Change in serum phosphate level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Percent Change in Serum Phosphate Level | Week 48 minus baseline | Percent change in serum phosphate level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as percent change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Serum 1,25-dihydroxyvitamin D Level | Week 48 minus baseline | Change in serum 1,25-dihydroxyvitamin D level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Percent Change in Serum 1,25-dihydroxyvitamin D Level | Week 48 minus baseline | Percent change in serum 1,25-dihydroxyvitamin D level from baseline to 48 weeks. Measurements were taken at baseline and week 48. Analysis was done as percent change in median value between baseline and week 48. Change = 48 weeks minus baseline. |
| Change in Serum Ratio of Renal Tubular Maximum Reabsorption Rate of Phosphate to Glomerular Filtration Rate (TmP/GFR) | Week 48 minus baseline | Change in serum ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Percent Change in Serum Ratio of Renal Tubular Maximum Reabsorption Rate of Phosphate to Glomerular Filtration Rate (TmP/GFR) | Week 48 minus baseline | Percent change in serum ratio of renal tubular maximum reabsorption rate of phosphate to glomerular filtration rate (TmP/GFR) from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as percent change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Fibrous Dysplasia Lesion Activity Using Fluorine-18 Sodium Fluoride Positron Emission Tomography/Computed Tomography (18F-NaF PET/CT) Scan | Week 48 minus baseline | Change in fibrous dysplasia lesion activity using Fluorine-18 Sodium Fluoride Positron Emission Tomography/Computed Tomography (18F-NaF PET/CT) scan from baseline to week 48. 18F-NaF PET/CT scan was done at baseline and week 48 and total lesion activity units were calculated from each scan. Change in lesion activity was compared between timepoints, baseline and week 48. Change = 48 weeks minus baseline. |
| Change in Serum Procollagen 1 N-terminal Propeptide (P1NP) Level | Week 48 minus baseline | Change in serum procollagen 1 N-terminal propeptide (P1NP) level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Percent Change in Serum Procollagen 1 N-terminal Propeptide (P1NP) Level | Week 48 minus baseline | Percent change in serum procollagen 1 N-terminal propeptide (P1NP) level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as percent change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Serum Beta Crosslaps C-telopeptides (CTX) Level | Week 48 minus baseline | Change in serum beta crosslaps C-telopeptides (CTX) level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Percent Change in Serum Beta Crosslaps C-telopeptides (CTX) Level | Week 48 minus baseline | Percent change in serum beta crosslaps C-telopeptides (CTX) level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as percent change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Serum Osteocalcin Level | Week 48 minus baseline | Change in serum osteocalcin level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Percent Change in Serum Osteocalcin Level | Week 48 minus baseline | Percent change in serum osteocalcin level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as percent change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Serum Alkaline Phosphatase Level | Week 48 minus baseline | Change in serum alkaline phosphatase level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Percent Change in Serum Alkaline Phosphatase Level | Week 48 minus baseline | Percent change in serum alkaline phosphatase level from baseline to week 48. Measurements were taken at baseline and week 48. Analysis was done as percent change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Fibrous Dysplasia Lesion Cellularity | Week 48 minus baseline | Change in fibrous dysplasia lesion cellularity was assessed by minimally invasive bone biopsies at baseline and week 48 in only adult participants with capacity to consent to procedure. Bone biopsies assessed the count of cell density. Analysis was done as change in median cell density value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Muscle Strength Using the Manual Muscle Test Scale | Week 48 minus baseline | Muscle strength was assessed using the manual muscle test (MMT) scale. MMT is a clinical technique to assess the strength of individual muscles or muscle groups based on ability to move against gravity and resist applied external pressure on a 0-5 scale, with 0 (no contraction), 1 (trace), 2 (poor) (movement with gravity eliminated), 3 (fair) (movement against gravity), 4 (good) (movement against gravity with moderate resistance), and 5 (normal strength). Higher number indicates better muscle resistance and strength. Each muscle group was assessed at baseline and week 48. Analysis was done for each muscle as change between baseline and week 48 (week 48 - baseline). |
| Change in Muscle Range-of-motion | Week 48 minus baseline | Muscle range-of-motion was measured as the degree of movement of muscles. Assessment was done at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Walking Speed Measured by the 9-minute Walk Test (9MWT) | Week 48 minus baseline | Change in walking speed was measured by the 9-minute walk test from baseline to week 48. The 9-minute walk test (9MWT) is a measure of physical capacity and participants are instructed to run or walk over a time period of nine minutes. The 9-minute walk test distance (9MWD) is the total distance walked in meters during the 9MWT and greater distance walked means better physical capacity. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Quality of Life Measured by the 36-Item Short Form Health Survey (SF-36) Score | Week 48 minus baseline | The change in quality of life for the adult participants was assessed using the Short Form Health Survey (SF-36). SF-36 is a 36-item patient-reported survey of patient health status that consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The higher the score, the less disability. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Health-related Quality of Life Measured by the 10-Item Short Form Health Survey (SF-10) - Physical Summary Score (PHS) | Week 48 minus baseline | The change in quality of life for the pediatric participants was assessed using the Short-Form Health Survey-10 (SF-10). The Short-Form Health Survey (SF-10) is a 10-item parent-completed questionnaire that covers a wide range of domains affecting a child's functional health and well-being. The SF-10 is scored to produce two norm-based summary scores: a Physical Summary Score (PHS) and a Psychosocial Summary Score (PSS), each with a mean of 50 and a standard deviation of 10. Analysis was based on the PHS. The PHS scale is directly transformed into a 0-100 scale. The higher the score, the less disability. Measurements were taken for the Physical Summary Score (PHS) at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Patient Reported Outcome Measurement Information System (PROMIS) Score (Pediatric and Parent Proxy Version 1.0) - Pain Intensity Domain | Week 48 minus baseline | The Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity (Pediatric and Parent Proxy version 1.0) domain measures pain intensity in children, with pediatric self-report versions for ages 8-17 and parent proxy-report versions for children aged 5-17. This measure uses a standard scale to assess the level of pain over the past seven days, and for the current moment, providing a quantitative score that reflects the severity of the pain. The scale consist of three items with each scored on a 5-point Likert scale, 1-5 with lowest score of 3 and highest of 15. The raw score is converted to a T-score with a mean of 50 and standard deviation of 10. Higher scores indicates greater pain intensity. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Patient Reported Outcome Measurement Information System (PROMIS) Score (Adult Version 2.0) - Pain Intensity Domain | Week 48 minus baseline | The Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity (Adult version 2.0) - Pain Intensity domain is a universal, self-report measure of how much pain a person is experiencing. This measure uses a standard scale to assess the level of pain over the past seven days, and for the current moment, providing a quantitative score that reflects the severity of the pain. The scale consist of three items with each scored on a 5-point Likert scale, 1-5 with lowest score of 3 and highest of 15. The raw score is converted to a T-score with a mean of 50 and standard deviation of 10. Higher scores indicates greater pain intensity. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Patient Reported Outcome Measurement Information System (PROMIS) Score (Pediatric and Parent Proxy Version 2.0) - Pain Inference Domain | Week 48 minus baseline | The Patient Reported Outcome Measurement Information System (PROMIS) (Pediatric and Parent Proxy version 2.0) - Pain Inference Domain assesses how pain impacts daily life, sleep, and enjoyment in children, with the Pediatric version being self-reported by children aged 8-17 and the Parent Proxy version completed by a parent or guardian for their child aged 5-17. This measure uses a standard scale to assess the level of pain interference over the past seven days, and for the current moment, providing a quantitative score that reflects the severity of the pain interference. Each item is rated on a 5-point scale (1-5). The scores are then summed and converted into a T-score, with a mean of 50 and standard deviation of 10. Higher scores indicate greater pain interference. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Patient Reported Outcome Measurement Information System (PROMIS) Score (Adult Version 1.1) - Pain Inference Domain | Week 48 minus baseline | The Patient-Reported Outcomes Measurement Information System (PROMIS) (Adult version 1.1) - Pain Inference scale assesses the impact of pain on social, physical, cognitive, emotional, and recreational activities, as well as sleep and life enjoyment. The scale consists of 12 items and each item is rated on a 5-point scale (1-5). The scores are then summed and converted into a T-score, with a mean of 50 and standard deviation of 10. Higher scores indicate greater pain interference. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Patient Reported Outcome Measurement Information System (PROMIS) Score (Pediatric and Parent Proxy Version 2.0) - Mobility Lower Extremity Domain | Week 48 minus baseline | The Patient Reported Outcome Measurement Information System (PROMIS) (Pediatric and Parent Proxy version 2.0) Mobility Lower Extremity domain assesses self-perceived mobility in children, with the Pediatric version being self-reported by children aged 8-17 and the Parent Proxy version completed by a parent or guardian for their child aged 5-17. This measure uses a standard scale to assess lower extremity mobility by asking about activities such as getting up from a chair or running over the past seven days. Each item is rated on a 5-point scale (1-5). The scores are then summed and converted into a T-score, with a mean of 50 and standard deviation of 10. Higher scores indicate greater mobility. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Patient Reported Outcome Measurement Information System (PROMIS) Score (Adult Version 2.0) - Mobility Lower Extremity Domain | Week 48 minus baseline | The Patient Reported Outcome Measurement Information System (PROMIS) (Adult version 2.0) Mobility Lower Extremity Domain assesses an adult's self-perceived ability to perform physical tasks related to mobility and lower extremity function, such as getting out of a chair or walking. This measure uses a standard scale to assess lower extremity mobility by asking about mobility activities over the past seven days. Each item is rated on a 5-point scale (1-5). The scores are then summed and converted into a T-score, with a mean of 50 and standard deviation of 10. Higher scores indicate greater mobility. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Patient Reported Outcome Measurement Information System (PROMIS) Score (Pediatric and Parent Proxy Version 2.0) - Fatigue Domain | Week 48 | The Patient Reported Outcome Measurement Information System (PROMIS) (Pediatric and Parent Proxy version 2.0) Fatigue domain assess the level and impact of fatigue in children and adolescents, with the Pediatric version being self-reported by children aged 8-17 and the Parent Proxy version completed by a parent or guardian for their child aged 5-17. This measure uses a standard scale to assess the level of fatigue over the past seven days. Each item is rated on a 5-point scale (1-5). The scores are then summed and converted into a T-score, with a mean of 50 and standard deviation of 10 based on a US general population. Higher scores indicate worsening fatigue. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Change in Patient Reported Outcome Measurement Information System (PROMIS) - Short Form - Fatigue 13a (Adult FACIT 13a v1.0) | Week 48 | The Patient Reported Outcome Measurement Information System (PROMIS) Functional Assessment of Chronic Illness Therapy Fatigue (FACIT-F) Scale is a 13-item patient-reported outcome (PRO) questionnaire that captures the individual's subjective experience of their fatigue. The fatigue domain is scored on a 5-point Likert scale and converted into standardized T-scores with a mean of 50 and a standard deviation of 10 based on a US general population. Higher score indicates less fatigue. Measurements were taken at baseline and week 48. Analysis was done as change in median value between baseline and week 48. Change = week 48 minus baseline. |
| Proportion of Participants With Change in Activities of Daily Living (ADL) Questions | Week 48 minus baseline | Proportion of participants with change in activities of daily living (ADL) questions from baseline to week 48 was assessed using a study developed questionnaire. Participants and/or caregivers were asked to provide a list of three activities of daily living that were affected by fibrous dysplasia skeletal features at home or school/work (e.g., mobility, climbing stairs, dressing, playing with peers, catching a bus, etc.) and to rate the extent of impact upon their activity level using one of the option: * Very Much Improved * Much Improved * Minimally Improved * No Change * Minimally Worse * Much Worse * Very Much Worse These activities were assessed at baseline, then reassessed at Week 24 and Week 48. Analysis was done as proportion of participants reporting "much improved" or "very much improved" in Activities of Daily Living Questions. Change = Week 48 minus baseline. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAlison M Boyce, M.D.
National Institute of Dental and Craniofacial Research (NIDCR)
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 7 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 5 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants |
| Race (NIH/OMB) White | 8 Participants |
| Sex: Female, Male Female | 8 Participants |
| Sex: Female, Male Male | 4 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 12 |
| other Total, other adverse events | 12 / 12 |
| serious Total, serious adverse events | 2 / 12 |
Outcome results
None listed